July 27, 2011 at 06:30 AM EDT
Lilly Study Could Sink Prospects for Alzheimer’s Treatments
Eli Lilly's semagacestat failure raises questions about safety of its class of drug; Bristol-Myers still churning ahead with development of secretase inhibitor.
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here